论文部分内容阅读
本文自１９９１年１月以来．进行了静脉输注胎肝细胞悬液干扰化疗药物降白副反应的医学序贯试验。实验组病人静脉输注４～６月胎龄胎肝细胞悬液１６００～４０００ｍｌ（浓度５～７×１０９个／Ｌ），对照组按常规方法升白。通过２８例病人的序贯试验发现化疗期间输注胎肝细胞悬液的病人骨髓抑制发生延迟，持续时间短，程度减轻，从而为化疗正常进行提供基本条件。结论；胎肝细胞悬液输注可干扰化疗药物降白副反应的发生。
This article has been since January 1991. Intravenous infusion of fetal liver cell suspension interfered with chemotherapy sequential drug side effects. Patients in the experimental group were intravenously infused with fetal liver cell suspension of 1600-4000 ml (concentration 5-7×109 cells/L) for 4 to 6 months of gestation, and the control group was elevated by routine methods. Sequential trials of 28 patients found that bone marrow suppression in patients receiving infusion of fetal liver cell suspension during chemotherapy was delayed, with a short duration, and reduced in extent, thus providing the basic conditions for normal chemotherapy. Conclusion: Fetal liver cell suspension infusion can interfere with the occurrence of side effects of chemotherapy drug whitening.